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Introduction
Chimeric antigen receptor (CAR) T cells targeting CD19 are an effective therapy for B cell malignancies. 
However, expanding the reach of  this treatment beyond B cell malignancies is challenging due to the paucity 
of  antigens that can be safely targeted without causing undue toxicity. One strategy to circumvent this prob-
lem is to genetically delete the target antigen from hematopoietic stem cells (HSCs), which can then generate 
an antigen-negative hematopoietic system that is resistant to CAR T cell therapy. As proof  of  principle, we 
and others have shown that CD33, a myeloid antigen, can be safely deleted from HSCs and can generate 
CD33– myeloid cells that are resistant to CD33-targeting immunotherapy including CAR T cells (1–3).
We now propose to extend this strategy to T cell antigens. T cell malignancies pose an additional chal-
lenge to CAR T cell therapy due to the shared expression of  target antigens between normal and malignant 
T cells. To overcome this problem, our group has developed CAR T cells targeting CD7 that are genetically 
edited to lack both CD7 and the T cell receptor (universal CD7-targeting chimeric antigen receptor T cells 
[UCART7]) in order to avoid fratricide and permit the use of  allogeneic T cells for treatment (4). Other 
groups have also independently developed strategies to mitigate fratricide by removing CD7 expression 
from CAR T cells (5, 6). However, none of  these strategies address the limitation of  toxicity to normal T 
and NK cells that may result in sustained immunodeficiency and susceptibility to opportunistic infections.
Here, we show that eliminating all CD7-expressing cells would be detrimental to human health, as 
this would eliminate most of  the cytotoxic effector cells of  the immune system, and the remaining CD7– T 
cells are not capable of  the full spectrum of  immune cell function. We then show that genetic deletion of  
the CD7 gene in HSCs is feasible without impairing their ability to engraft and differentiate into mature 
hematopoietic cells, including T and NK cells. Furthermore, we find that CD7-KO T cells are functionally 
indistinguishable from control T cells and retain properties of  CD7+ T cells that are lacking in CD7– T cells. 
Finally, we show that CD7-KO T and NK cells are resistant to UCART7 attack and, thus, can preserve host 
immunity after CAR T cell treatment.
Results
Characterization of  CD7– T cells. To confirm the previously reported expression pattern of  CD7 (7, 8), we 
evaluated CD7 expression in healthy donor peripheral blood mononuclear cells (PBMCs). Consistent with 
Targeting T cell malignancies with universal CD7-targeting chimeric antigen receptor T cells 
(UCART7) can lead to profound immune deficiency due to loss of normal T and NK cells. While a 
small population of endogenous CD7– T cells exists, these cells are unlikely to be able to repopulate 
the entire immune repertoire after UCART7 treatment, as they are limited in number and 
proliferative capacity. To rescue T and NK cells after UCART7, we created hematopoietic stem cells 
genetically deleted for CD7 (CD7-KO HSCs). CD7-KO HSCs were able to engraft immunodeficient 
mice and differentiate into T and NK cells lacking CD7 expression. CD7-KO T and NK cells could 
perform effector functions as robustly as control T and NK cells. Furthermore, CD7-KO T cells were 
phenotypically and functionally distinct from endogenous CD7– T cells, indicating that CD7-KO 
T cells can supplement immune functions lacking in CD7– T cells. Mice engrafted with CD7-KO 
HSCs maintained T and NK cell numbers after UCART7 treatment, while these were significantly 
decreased in control mice. These studies support the development of CD7-KO HSCs to augment 
host immunity in patients with T cell malignancies after UCART7 treatment.
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prior reports, we found that CD7 was expressed in the majority of  T cells (median 90%) and NK cells 
(median 97%) (Figure 1A). There was a discernable CD7– T cell population in all subjects that was slightly 
more prominent in CD4+ cells (Figure 1B). Immunophenotyping by FACS showed decreased CCR7 and 
increased CD45RO expression in the CD7– T cell population, so that the majority of  cells had an effector 
memory phenotype (Figure 1C). Of note, these cells were obtained from adult donors across a broad age 
spectrum (range, 22–73 years; median age, 54). T cells from cord blood were predominantly naive, as expect-
ed, and uniformly expressed CD7 (Supplemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.149819DS1).
To further profile CD7– T cells, we explored publicly available single-cell RNA sequencing (RNA-seq) 
data sets of  healthy donor PBMCs (9–11). We found that CD7 transcript levels in T cells (defined as cells 
expressing TRAC and CD3E) in younger individuals (6–16 years) were significantly higher than older indi-
viduals (approximately 20–80 years), while T cells from supercentenarians (>110 years) had much lower 
expression of  CD7 than the other 2 age cohorts (Supplemental Figure 1B). We were also able to verify 
that CD7 expression was higher in CD8+ T cells than in CD4+ T cells (Supplemental Figure 1C). Differ-
ential gene expression analysis of  CD7– versus CD7+ T cells confirmed a small but significant decrease in 
expression of  CCR7 and SELL, and showed increased expression of  effector molecules such as GZMA and 
GZMH (Supplemental Figure 1D).
In terms of  functionality, CD7– T cells were for the most part intact in their ability to respond to PMA 
and IL-2, and to degranulate and produce cytokines (Supplemental Figure 2, A–C). However, we noted 
that CD7 expression increased in T cells after activation with CD3/CD28 beads, from median expression 
levels at baseline of  92.6%–97% after activation (P = 0.0056), suggesting that either CD7– T cells express 
CD7 upon activation or CD7– T cells are at a proliferative disadvantage compared with CD7+ T cells. To 
investigate this further, we separated CD7+ and CD7– T cell populations and activated them separately, and 
we found that, indeed, a proportion of  CD7– T cells expressed CD7 after activation, from median expres-
sion of  8.1% at baseline to 39.6% after activation (P = 0.0002) (Figure 1, D and E). Additionally, we found 
that the growth of  CD7– T cells was greatly diminished as compared with CD7+ T cells (median 8-fold 
versus 56-fold, P = 0.02) (Figure 1F).
To further interrogate T cell function, we generated CAR T cells independently from CD7+ and CD7– T 
cell fractions, in addition to the bulk T cell population. CD7– T cells could be manufactured into CD19- and 
CD33-targeting CAR T cells that were able to kill tumor cells expressing the target antigen (Supplemen-
tal Figure 2, D and E). However, the expansion of  CAR T cells generated from CD7– T cells was greatly 
decreased as compared with bulk T cells or CD7+ T cells (Supplemental Figure 2, F and G), and CD7 
expression was upregulated on the CAR T cells during expansion (Supplemental Figure 2H).
To assess the susceptibility of  the different T cell populations to CD7-targeting therapy, we incubated 
activated total T cells, CD7+ T cells, and CD7– T cells with UCART7. We observed complete elimination 
of  CD7-expressing cells in all groups (Figure 1G), leading to loss of  greater than 90% of  total and CD7+ 
T cells (Figure 1H), as expected. CD7– T cell numbers were also reduced (range, 11%–60%), confirming 
that activated CD7– T cells can become susceptible to UCART7, leading to further reduction of  T cell 
numbers after this treatment.
CD7-KO HSCs can generate CD7-KO T and NK cells. We hypothesized that genetically deleting CD7 in HSCs 
could generate CD7– T and NK cells that would provide immune protection to patients undergoing UCART7 
treatment. We generated CD7-KO HSCs from human umbilical cord blood CD34+ cells using CRISPR/Cas9 
(Figure 2A), using the same guide RNA (gRNA) that we previously utilized to delete CD7 in T cells (4, 12). 
Next-generation sequencing (NGS) showed a median indel frequency of  84% at the CD7 gene locus, which 
is comparable with our prior experience when editing T cells (Figure 2B). NSGS mice injected with control 
or CD7-KO HSCs showed similar levels of  human cell engraftment, with differentiation into both myeloid 
and lymphoid lineages (Figure 2, C and D). Importantly, we found that T cells derived from CD7-KO HSCs 
showed significantly lower levels of  CD7 expression as compared with controls (Figure 2E). CD7 expression 
was also significantly reduced in the NK cells that emerged in CD7-KO HSC–engrafted mice (Figure 2F), and 
serial measurements of  CD7 surface protein expression in NK cells by flow cytometry correlated with degree 
of  CD7 gene mutations detected by NGS (Figure 2G).
To better illuminate the engraftment and function of  NK cells, we performed these same studies 
in NSG–huIL-15 mice (13). NSG–huIL-15 mice engrafted with control or CD7-KO HSCs had similar 
levels of  human cell engraftment (Supplemental Figure 3A), and robust human NK cell engraftment 
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Figure 1. CD7– T cells have limited proliferative capabilities and are potentially still susceptible to UCART7 after activation. (A–C) CD7 expression on 
healthy T and NK cells was measured by flow cytometry (n = 16 donors). (A) CD7 expression on T cells and NK cells. (B) CD7 expression on CD4+ and CD8+ 
T cell subsets (paired 2-tailed Student’s t test). (C) CD7– T cells exhibit a predominantly effector memory phenotype. Memory phenotype was defined by 
CD45RO and CCR7 expression, as depicted in the left panel. Asterisks denote statistical comparisons of the frequency of each group within CD7+ versus 
CD7– cells by 2-way ANOVA with multiple comparisons. (D–F) T cells were divided into CD7+ and CD7– fractions and activated with anti-CD3/CD28 beads, 
followed by serial cell counts and flow cytometry to evaluate CD7 expression (n = 8 donors). (D) CD7 expression significantly increases after T cell activa-
tion with anti-CD3/CD28 beads in both bulk T cells (left) and CD7– cells (right) (paired 2-tailed Student’s t test). (E) Representative flow cytometry plots 
showing increased CD7 expression in total and CD7– T cells after activation. (F) Maximum fold-expansion of CD7+, total, and CD7– T cells (1-way ANOVA with 
Tukey’s multiple-comparison test). Representative growth curve is shown on the right. (G and H) Activated T cells were incubated with UCART7 for 48 
hours, after which cell counts and percentage of CD7 of remaining CD3+ T cells were quantified by flow cytometry (n = 4 donors). All numbers are averages 
of 3 technical replicates. (G) Percentage of CD7 expression on CD3+ T cells at baseline and after incubation with UCART7. (H) Percent reduction of CD3+ 
T cells in each group after UCART7 treatment, calculated as the number of CD3+ cells in UCART7-treated groups divided by the number of CD3+ cells in 
untreated groups (1-way ANOVA with Tukey’s multiple-comparison test). **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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was seen with both control and CD7-KO HSCs (Supplemental Figure 3B). We also confirmed that CD7 
expression was markedly decreased in NK cells after CD7-KO by both flow cytometry and NGS (Sup-
plemental Figure 3, C and D).
To evaluate whether loss of  CD7 confers any growth advantage or disadvantage in hematopoietic cells, 
we compared the frequency of  mutations detected in the infused CD34+ cell product and in vivo differentiated 
Figure 2. CD7-KO HSCs can engraft and differentiate into T and NK cells lacking CD7 expression. (A) Experimental schema: Cord blood CD34+ cells were 
subject to CRISPR/Cas9 editing of the CD7 gene followed by injection into NSGS mice to assess for their ability to regenerate human hematopoiesis. (B) 
Next-generation sequencing of the CD7 gene in control and CD7-KO HSCs after gene editing and in vitro differentiation (n = 11 cord blood donors). (C) Serial 
measurements of peripheral blood human engraftment in NSGS mice injected with control or CD7-KO HSCs. (D) Peripheral blood human T cells (CD3+), B 
cells (CD19+), myeloid cells (CD33+), and NK cells (CD56+) measured at 14–16 weeks (n = 42 mice/group). (E) CD7 expression in T cells derived from control or 
CD7-KO HSCs in the peripheral blood (n = 25–27 mice/group) (left). Representative flow cytometry plots (right). (F) CD7 expression in NK cells derived from 
control or CD7-KO HSCs in the peripheral blood (n = 25–26/group) (G) CD7 expression on human NK cells measured by flow cytometry (left) and peripheral 
blood total CD7 gene mutations detected by NGS (right) (n = 7 mice/group, representative of 3 independent experiments). All statistical analyses were 
performed using unpaired 2-tailed Student’s t test. ****P < 0.0001.
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human cells after 16 weeks, and we found that the overall frequency of  CD7 gene mutations remained stable 
(Supplemental Figure 4A). To fully interrogate the regenerative potential of  CD7-KO HSCs, we injected con-
trol or CD7-KO HSCs into a cohort of  NSG mice and confirmed human engraftment (Supplemental Figure 
4B), and we then performed secondary transplants into NSGS mice. We found that CD7-KO HSCs retained 
their ability to engraft and differentiate into human T cells in the secondary recipients, with sustained loss of  
CD7 expression (Supplemental Figure 4, C–E).
CD7-KO T and NK cells are functional. To determine whether CD7-KO T cells were functionally intact, we 
interrogated human T cells obtained from control or CD7-KO HSC–engrafted NSGS mice. Control and CD7-
KO T cells both demonstrated appropriate activation of intracellular signaling pathways in response to PMA 
and IL-2 (Figure 3A). Degranulation (%CD107a) and intracellular cytokine production (%IL-2, IFN-γ, TNF-α, 
GM-CSF, MIP1b) in response to PMA/ionomycin was also intact in CD7-KO T cells (Figure 3B). To assess 
the functionality of CD7-KO NK cells, human NK cells obtained from NSG–huIL-15 mice were cultured with 
UM-SCC-9, a squamous cell carcinoma cell line with known susceptibility to NK cell–mediated cytotoxicity. 
We found that treatment with control or CD7-KO NK cells led to equivalent tumor cell killing (Figure 3C). 
Levels of CD16 and killer cell Ig-like receptor (KIR) expression was also comparable in control and CD7-KO 
NK cells (Figure 3D). To assess the ability of lymphoid cells to respond to cytokine stimulation in vivo, we 
administered NT-I7, a long-acting recombinant human IL-7 (14, 15), into NSGS mice engrafted with control 
or CD7-KO HSCs. As expected, levels of circulating human NK cell and T cell numbers increased after admin-
istration of NT-I7, and the absence of CD7 made no difference in the degree of response (Figure 3E).
CD7-KO T cells are distinct from CD7– T cells. We found that T cells derived from CD7-KO HSCs in NSGS 
mice had a slight decrease in the percentage of  CD4 (%CD4) and a commensurate increase in %CD8 expres-
sion that only manifested after several experiments were pooled (control, n = 22 mice; CD7-KO, n = 24 
mice) (Figure 4A). Detailed examination of  the CD7+ and CD7– T cell fractions in each group revealed that 
the control T cells had increased CD4 expression in the CD7– fraction, as seen in normal human T cells; 
however, in CD7-KO T cells this effect was lost (Figure 4B). Therefore, even though CD7-KO T cells had 
less CD7expression, there was increased expression of  CD8 as compared with control T cells. Additionally, 
while control T cells had the expected decrease in naive cells in the CD7– fraction, CD7-KO T cells retained 
a naive population within the CD7– cells (Figure 4C). To measure the expansion capacity of  CD7-KO T 
cells, we stimulated control or CD7-KO T cells with CD3/CD28 beads and found no significant difference 
in expansion between the 2 groups (Figure 4D). Additionally, while both control and CD7-KO T cells upreg-
ulated CD7 expression after activation, the absolute difference in CD7 expression was unchanged, indicat-
ing that a static population of  T cells unable to express CD7 remained in the CD7-KO group (Figure 4E).
CD7-KO T and NK cells are resistant to UCART7. We proceeded to inject control or CD7-KO HSC–engraft-
ed mice with UCART7, to ensure that these cells were indeed resistant to CD7-targeting therapy (Figure 
5A). UCART7 was generated from allogeneic T cells that were deleted for TRAC and CD7 genes, followed by 
insertion of  a CD7-targeting CAR. T cells derived from the HSCs were easily distinguishable from the adop-
tively transferred T cells based on expression of  CD3 (unique to HSC-derived T cells) and CD34 (a detection 
marker for UCART7) (Figure 5B). We observed an immediate loss of  human CD7+ cells in the peripheral 
blood of  both groups of  mice, and this loss led to a significant decrease in human T cells in the controls, while 
T cells were maintained in mice engrafted with CD7-KO HSCs (Figure 5, C and D). Peripheral blood NK 
cells were also better maintained in mice with CD7-KO HSCs as compared with mice with control HSCs 
after UCART7 treatment (Figure 5E). Of note, we detected minimal numbers of  circulating UCART7 cells in 
these experiments, and this was not significantly different between the 2 groups (Figure 5F).
To ensure that the antitumor activity of UCART7 is preserved in the setting of CD7-KO HSCs, we pro-
ceeded to add CCRF-CEM, a CD7+ T-ALL cell line, to the HSC-engrafted mice prior to UCART7 injection 
(Figure 6A). Tumor control was comparable in mice with control or CD7-KO HSCs as compared with a 
cohort of mice without prior HSC engraftment (Figure 6B). We observed a trend toward reduction of T cell 
numbers in the control HSC-engrafted mice, although this was not statistically significant, while T cell numbers 
were stable in CD7-KO HSC–engrafted mice (Figure 6C). Control HSC-engrafted mice had the expected loss 
of NK cells, while in CD7-KO HSC–engrafted mice, NK cells could still be detected (Figure 6D). Intriguingly, 
UCART7 expansion was more robust in mice with control HSCs than with CD7-KO HSCs (Figure 6E).
Targeted deep sequencing does not reveal off-target mutations in CD7-KO HSCs. Off-target mutations is a con-
cern when performing gene editing in HSCs, as deleterious mutations in HSCs can have long-term and 
profound consequences. We previously performed GUIDE-seq (16), an unbiased genome-wide method to 
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Figure 3. CD7-KO T and NK cells remain functional. (A and B) Human T cells in the spleens of NSGS mice engrafted with control or CD7-KO HSCs were 
functionally interrogated in vitro. (A) Levels of pErk1/2 and pSTAT5 were assessed in control and CD7-KO T cells at baseline and in response PMA and 
IL-2 stimulation (n = 4 mice/group) (unpaired 2-tailed Student’s t test). (B) Degranulation (%CD107a) and intracellular cytokine production (%IL-2, IFN-γ, 
GM-CSF, TNF-α, MIP1b) in control and CD7-KO T cells was measured after stimulation with PMA and ionomycin. (n = 7 mice/group) (unpaired 2-tailed 
Student’s t test). (C and D) Human NK cells purified from the spleens of NSG–huIL-15 mice engrafted with control or CD7-KO HSCs were interrogated 
in vitro. (C) Control and CD7-KO NK cells were incubated at different E:T ratios with UM-SCC-9, a human squamous cell carcinoma cell line, and tumor 
cell numbers were serially measured over time using the Incucyte Live Cell Analysis system (data expressed as median range of triplicate wells) (2-way 
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identify DNA double-strand breaks, in primary human T cells to identify off-target mutations after CRIS-
PR/Cas9 editing of  CD7. We interrogated the 4 off-target mutation sites identified by GUIDE-seq in CD7-
KO HSCs, and we also added 5 off-target sites that were predicted in silico to have a high degree of  homol-
ogy to the CD7 gRNA. NGS across these 9 locations in 3 different primary human CD34+ cells after CD7 
editing revealed no off-target mutations, despite a high degree of  on-target mutations (Table 1).
Discussion
CD7 is an attractive target for immunotherapy of  T cell malignancies, as it is broadly expressed across a 
wide range of  T cell lineage tumors. However, CD7 is also present on the majority of  normal T cells and 
NK cells, and targeting CD7 could lead to prolonged immunosuppression. Our work examines whether 
treatment with CD7-targeting CAR T cells could lead to intolerable toxicity and, if  so, whether we could 
circumvent this by deleting the CD7 gene from HSCs to generate T and NK cells lacking CD7 expression 
but still capable of  host protection.
We first examined whether the CD7– T cells that are found in healthy subjects could be sufficient to 
provide protective immunity after CD7-targeting CAR T cell treatment. In healthy adults, elimination of  
all CD7+ cells will lead to complete loss of  NK cells and loss of  90% of  T cells. The remaining CD7– T cells 
predominantly show the CD4+ effector memory phenotype, and while they retain effector functions such 
as cytokine production and cytotoxicity, they do not expand robustly in response to CD3/CD28 stimula-
tion. Our results corroborate prior studies of  CD7– T cells that reported increased expression of  CD4 and 
CD45RO and a lower proliferative response to various mitogens (8, 17). Furthermore, we observed that 
30%–50% of  CD7– T cells can express CD7 and become susceptible to CD7-targeting CAR T cells after 
activation, leading to further decrease of  the functional T cell repertoire.
Of  note, CD7– T cells are not present in cord blood, and single-cell RNA-seq data of  normal PBMCs 
show lower levels of  CD7 transcript expression in T cells from older individuals. Supercentenarians, defined 
as individuals of  age greater than 110, have particularly low levels of  CD7+ T cells. We can hypothesize 
from these findings that loss of  CD7 may be a surrogate marker for aging of  the T cell repertoire. Practical-
ly, our findings suggest that CD7-targeting therapy may lead to more profound T cell depletion in pediatric 
patients, and these patients may be in the most need for strategies to circumvent T cell toxicity.
Therefore, we proceeded to generate CD7-KO HSCs, with the goal of  creating CD7-KO T and NK 
cells that were resistant to CD7 targeting therapy while still retaining function. We examined the engraft-
ment and differentiation profile of  CD7-KO HSCs in 3 different strains of  mice — NSG, NSGS, and 
NSG–huIL-15 — to ensure that these cells retained their ability to reconstitute the full spectrum of  human 
hematopoiesis. The hematopoietic system arising from CD7-KO HSCs was nearly identical to that of  con-
trol HSCs, regardless of  host mouse strain, with the exception of  decreased surface CD7 expression in T 
and NK cells derived from CD7-KO HSCs. While the extent of  CD7 mutations detected in each mouse 
diverged over time, likely representing outgrowth of  dominant clones from the initial HSC product, the 
average mutation rate within each experiment remained stable. Therefore, our results at this time do not 
support any fitness advantage or disadvantage of  CD7 mutations on the hematopoietic system.
Human T cells derived from CD7-KO HSCs did not exhibit any functional deficiencies in terms of  intra-
cellular signaling, degranulation, cytokine production, and response to IL-7 stimulation. CD7-KO NK cells 
were also comparable with control NK cells in terms of  cytotoxicity, surface marker expression, and IL-7 
response. One point that was particularly interesting to us was that the properties of  CD7– T cells, such as 
lack of  CCR7 expression and reduced proliferation, were not recapitulated in CD7-KO T cells. These results 
indicate that CD7-KO T cells more closely resemble bulk T cells (that are predominantly CD7+) than phys-
iologically CD7– T cells, and they provide evidence that CD7-KO T cells could restore immune function 
after CD7-targeting therapy that would otherwise be limited to the function of  CD7– T cells alone. Of note, 
multiple groups have independently generated methods to remove CD7 from mature T cells so that they could 
be generated into CD7-targeting CAR T cells, and they have shown that both the proliferative and cytotoxic 
functions of  CD7-KO CAR T cells remain intact (4–6).
ANOVA with multiple comparisons). (D) Expression of CD16 and KIR was measured in control and CD7-KO NK cells. (E) Mice engrafted with control or CD7-
KO HSCs were treated with NT-I7, a long-acting IL-7 agonist, s.c. every 2 weeks starting 1 week after HSC injection for 7 doses total (n = 7–8 mice/group). 
Numbers of peripheral blood human NK cells and T cells are shown at 4 weeks and 15 weeks, respectively, after HSC engraftment (1-way ANOVA with 
Holm-Sidak multiple-comparison test). *P < 0.05, **P < 0.01, ****P < 0.0001.
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One limitation of  our studies is that the T cell engraftment was highly variable, ranging from 0.6% to 
97% of  human cells in the peripheral blood in NSGS mice. This may be because the ex vivo gene editing 
prior to injection decreased the repopulating capacity of  the cord blood CD34+ cells, and higher cell doses 
may be necessary to improve the reliability of  T cell engraftment. Several of  our experiments required 
large numbers of  mice to meet statistical significance due to this variability within the experimental model. 
Therefore, we cannot exclude the possibility that subtle qualities unique to CD7-KO T cells may exist, but 
these are buried within the variability of  the system.
An additional limitation is that the majority of  our experiments were performed in NSGS mice, as this 
strain supports rapid and robust T cell engraftment but only expresses CD7 in around 50% of  the human T 
cells that emerge after HSC engraftment. This is likely due to high proportions of  CD4+ and CD45RO+ T 
cells in these mice (18), 2 markers that inversely correlate with CD7 expression. In this setting, it is difficult 
to ascertain the function of  CD7-KO T cells solely based on the absence of  CD7 expression, since this will 
be a mixed population that contains WT CD7– T cells and CD7-KO T cells; therefore, again, our studies 
would not be able to detect subtle differences present only in CD7-KO T cells. Additionally, T cells generated 
Figure 4. CD7-KO T cells are phenotypically and function-
ally distinct from CD7– T cells. (A) CD4 and CD8 expression 
on T cells generated from control or CD7-KO HSCs engraft-
ed in NSGS mice (n = 22–24/group). (B) CD4 expression on 
CD7+ or CD7– T cells derived from control or CD7-KO HSCs (n 
= 15/group). (C) Naive cells (CCR7+CD45RO–) within the CD7+ 
and CD7– T cell fractions in control or CD7-KO T cells (n = 10/
group). (D) Human T cells derived from control or CD7-KO 
HSCs were expanded in vitro with anti-CD3/CD28 beads (n 
= 6/group) (E) CD7 expression at baseline and 3 days after 
activation in control and CD7-KO T cells (n = 5/group). Sta-
tistical analyses were performed using unpaired 2-tailed 
Student’s t test (A and D) or paired Student’s t test (B and 
C). *P < 0.05, **P < 0.01.
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in humanized NSGS mice are not fully functional due to lack of  thymic education, precluding our ability 
to perform in vivo functional experiments, such as immunization or skin grafts. Further investigations with 
more advanced models will be required to address these limitations.
Therefore, we do not preclude the possibility that lack of  CD7 may still have functional consequences 
that may perhaps manifest when T or NK cells are challenged with specific biologic stressors. On this note, 
CD7 is known to contribute to T and NK cell activation in vitro (19, 20), and while genetic deletion of  CD7 
in mice does not impair T cell development or major functions (21, 22), CD7-KO mice have been shown to 
be resistant to LPS-induced shock (23). In humans, the full impact of  CD7 deletion may well only manifest 
after long-term follow-up of  patients after CD7-KO HSC transplantation. The risks of  this treatment will 
need to be balanced carefully with the potential benefits for patients with incurable T cell malignancies.
The addition of  UCART7 to HSC-engrafted mice led to reduction of  T cells and NK cells in mice with 
control HSCs, while these cells were better preserved in mice with CD7-KO HSCs. In the non–tumor- 
bearing mice, these results were statistically significant, despite the variability of  T cell engraftment and 
the high percentage of  CD7– T cells in mice with control HSCs. Injection of  CCRF-CEM tumor cells 
prior to UCART7 treatment still led to the expected decrease in human T and NK cells without any 
Figure 5. T cells and NK cells are better preserved in mice with CD7-KO HSCs after UCART7 treatment. (A) Schema: NSGS mice  engrafted with either 
control or CD7-KO HSCs were treated with UCART7 after 15 weeks of engraftment (n = 14/group). (B) Gating strategy to identify the different T cell popu-
lations. Within the human CD45+ cell population, HSC-derived T cells express CD3, while UCART7 lacks CD3 but can be identified by expression of human 
CD34, a selection marker inserted with the CAR. (C) Peripheral blood CD7+ expression and numbers of T cells in control and CD7-KO HSC–engrafted mice. 
(D) Representative flow cytometry plots showing CD7 expression in T cells before and after UCART7 treatment. (E) CD7 expression on peripheral blood NK 
cells, and numbers before and after UCART7 treatment. (F) Peripheral blood UCART7 numbers 1 week after injection. Statistical analyses were performed 
using paired 2-tailed Student’s t test (C) or unpaired 2-tailed Student’s t test (E and F).  *P < 0.05, **P < 0.01.
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compromise of  antitumor effect. It is intriguing that mice with CD7-KO HSCs and tumor, followed by 
UCART7 treatment, had less detectable UCART7 expansion in the peripheral blood than mice with 
control HSCs. This may be due to decreased antigen burden seen by UCART7 when CD7 is deleted, or 
alternatively due to rejection of  UCART7 by the UCART7-resistant CD7-KO T and NK cells. We hope 
to investigate the mechanism behind these findings in future studies.
Finally, we note that gene editing of  HSCs is still in early stages, and there are understandable trep-
idations when applying this modality in human subjects. In particular, CRISPR-Cas9 gene editing of  
HSCs has only recently entered human clinical trials (24, 25), and we still await the long-term effects of  
this technology. Investigations to date have shown that CRISPR-Cas9 gene editing can be done in HSCs 
without undue toxicity from the editing procedure. However, off-target genotoxicity remains a major 
concern, as this will be specific to the gRNA used in each experiment and cannot be broadly generalized 
as safe. On this note, we looked at several off-target sites related to the CD7 gRNA that were identified 
both experimentally through GUIDE-seq in primary human T cells and computationally through in 
silico prediction models. We did not find any off-target editing primary human CD34+ cells in any of  
the predicted off-target sites that we queried, despite high levels of  on-target mutations. These results are 
consistent with other studies investigating CRISPR/Cas9 off-target activity in HSCs (25–27), where min-
imal off-target events were detected as long as the gRNA was chosen carefully. However, this does not 
preclude the possibility of  off-target sites unique to HSCs that were not identified through our prediction 
models, or of  off-target editing specific to individuals with certain single-nucleotide variations. All of  
these possibilities will need to be kept in mind when utilizing this technology.
Figure 6. UCART7 antitumor efficacy is not impaired by the presence of CD7-KO hematopoiesis. (A) Schema: NSGS mice engrafted with either control 
or CD7-KO HSCs were injected with CCRF-CEM, a CD7+ T-ALL cell line, followed by treatment with UCART7. A separate cohort of mice were injected with 
CCRF-CEM only, or CCRF-CEM and UCART7 without prior HSC engraftment (n = 5–6/group). (B) Serial tumor burden measured by bioluminescence imaging 
for each treatment group, with tumor-only control as reference. Each line represents 1 mouse. (C) Peripheral blood T cell counts in control or CD7-KO HSC 
and tumor-engrafted mice. (D) NK cells before and after UCART7 treatment in mice with HSCs and concurrent tumor. (E) UCART7 expansion in peripheral 
blood. Statistical analyses were performed using paired 2-tailed Student’s t test (D) or unpaired 2-tailed Student’s t test (E). *P < 0.05.
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In summary, we show that CD7-KO HSCs can generate functional T cells that lack CD7 expression and 
are, thus, resistant to CD7-targeting CART treatment. These results advance the concept of  genetic deletion 
of  cell surface markers in HSCs as a strategy to avoid the hematopoietic toxicity of  antigen-specific immu-
notherapy. Prior work in this field has focused solely on CD33, a myeloid antigen, confining the reach of  
this strategy to myeloid malignancies. We now show that CD7, a T cell antigen, can also be a viable target, 
opening up the field to T cell malignancies. We can further postulate that, potentially, a large number of  
cell-surface antigens exist that may be safely removed from HSCs without untoward effects, and this may be 
exploited therapeutically in the future, especially as we gain more clinical experience with gene-edited HSCs.
Methods
Evaluation of  CD7– T cells. Normal donor PBMCs were obtained from leukoreduction chambers of anonymous 
platelet donors. Cord blood units were obtained from the St. Louis Cord Blood Bank (St. Louis, Missouri, 
USA). To separate CD7+ and CD7– T cell fractions, T cells were first purified from PBMCs using a Human Pan 
T Isolation Kit (Miltenyi Biotec, 130-096-535) and separated on AutoMACS Pro Separator (Miltenyi Biotec). 
T cells were then labeled with CD7-biotin, followed by Anti-Biotin Microbeads (Miltenyi Biotec, 130-090-485), 
and positive and negative fractions were collected from the AutoMACS. Unselected T cells, CD7+ , and CD7– T 
cells were incubated with anti-CD3/CD28 beads (Thermo Fisher Scientific, 40203D) at a 3:1 bead/cell ratio and 
cultured in RPMI-1640 medium (Corning, 10-040-CM) containing 10% FBS (Thermo Fisher Scientific, 10-082-
139), 1% penicillin/streptomycin (Corning, 30-002-CI), 1% L-glutamine (Invitrogen, 35050079), 1% sodium 
pyruvate (Corning, 25-000-CI), 1% MEM nonessential amino acids (Corning, 25-050-CI), 2% HEPES buffer 
(Corning, 25-060-CI), and 50 µM 2-mercaptoethanol (Thermo Fisher Scientific, 21985-023). Cells were counted 
every 2–3 days, and CD7 expression was assessed serially by flow cytometry. For CAR T cell generation, bulk 
T cells, CD7+ and CD7– T cells were transduced with lentivirus containing previously published CAR19 (28) or 
CAR33 (29) constructs 1 day following activation.
Single-cell RNA-seq data from PBMCs. Single-cell RNA-seq data of healthy donor PBMCs were downloaded 
from NCBI Gene Expression Omnibus (accession nos. GSE171555, GSE166489) and from http://gerg.gsc.
riken.jp/SC2018/, and they were imported into Partek Flow Genomic Analysis Software. Raw count matrix 
files were filtered to only include cells with < 20% human mitochondrial DNA content and with a minimum 
of 200 and maximum of 20,000 expressed genes. Genes were filtered to only include those with expression 
levels > 1 in at least 99.9% of cells, followed by normalization. T cells within each sample were identified by 
expression of TRAC and CD3E genes and were further classified into CD4+ and CD8+ T cells by expression of  
CD4 and CD8A. Cells with CD7 gene expression were quantified within the CD4+ and CD8+ T cell populations. 
Differential gene expression was performed using Partek gene-specific analysis (GSA) comparing CD7+ and 
CD7– T cells within the 3 adult healthy donors in the GSE166489 data set, which was selected due to concur-
rent surface protein and gene expression evaluation.
Generation of  UCART7. UCART7 was manufactured as previously described (4), with the following modi-
fications. CD4+ and CD8+ T cells were selected from normal donor PBMCs and mixed at a 1:1 ratio, and they 
were activated with Transact (20 μL/mL, Miltenyi Biotec), followed by culture in Texmacs media supplemented 
Table 1. Off-target mutation analysis of CD7-KO HSCs
No Gene ID method
Donor A Donor B Donor C
Ctrl KO Ctrl KO Ctrl KO
1 CD7 On-target 99.3 2.1 99.4 8.0 99.3 13.4
2 PACRG GUIDEseq 99.6 99.6 99.6 99.6 99.5 99.5
3 ARHGEF4 GUIDEseq 99.4 99.4 99.4 99.4 99.5 99.3
4 HMGB1P22 GUIDEseq 99.6 99.5 99.3 99.3 99.4 99.0
5 CCBE1 GUIDEseq 97.6 98.2 97.8 98.2 98.3 98.3
6 AC016907.3 In silico 99.4 99.2 99.4 99.3 99.5 99.5
7 RP11-92A5.2 In silico 99.3 99.3 99.4 99.3 99.1 99.3
8 CTA-254O6.1 In silico 99.5 99.3 99.8 99.7 99.8 99.8
9 RPS3AP52 In silico 99.6 99.7 99.6 99.6 99.1 99.4
10 FUNDC2P2 In silico 99.5 99.3 99.4 99.3 99.5 99.4
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with 10 ng/mL IL-7 and 10 ng/mL IL-15. Two days after activation, T cells were washed and electroporated in 
100 μL Maxcyte EP buffer containing 15 μg TrueCut Cas9 Protein v2 (Thermo Fisher Scientific, A36499) and 
20 μg of each gRNA targeting CD7 and TRAC (Trilink) using the Maxcyte GT expanded T cell program #2. 
Two hours following electroporation, cells were transduced with a lentiviral vector containing a second-gener-
ation CD7-CAR with a 4-1BB cosignaling domain, which also contained the extracellular domain of human 
CD34 via a P2A peptide to enable detection and purification of CAR+ cells. CAR T cells were expanded for 
10–14 days prior to i.v. injection into mice (2 × 106 CAR+ cells/mouse) previously engrafted with control or 
CD7-KO HSCs. Residual CD3+ cells after gene editing were depleted from the UCART7 product using Human 
CD3 Microbeads (Miltenyi Biotec, 130-050-101).
UCART7 in vitro cytotoxicity. Unselected T cells, CD7+ or CD7– T cells from 4 different donors that had 
previously been expanded and frozen were thawed and incubated in vitro either alone or with UCART7 at 
a 1:1 E:T ratio for 48 hours in triplicate. Cells were then harvested and stained for flow cytometry using the 
following antibodies: CD3-PE/Cy7 (clone UCHT1, eBioscience, 25-0038-41), CD7-APC (clone M-T701, BD 
Biosciences, 561604), CD34-PE (clone QBEnd10 + Immu133 + Immu409, Beckman Coulter, IM1459U), and 
LIVE/DEAD fixable yellow (Thermo Fisher Scientific, L34967). Percent reduction of T cells were calculated 
by dividing the number of CD3+ T cells remaining in each group after UCART7 treatment over the number of  
CD3+ T cells remaining in each group without UCART7 treatment.
Gene editing of  HSCs. On day 1, human CD34+ cells were purified from fresh cord blood units using a CD34 
MicroBead Kit (Miltenyi Biotec, 130-046-702). Cells were cultured overnight in StemSpan SFEM (Stemcell 
Technologies, 09600) with 100 ng/mL of stem cell factor (SCF; Peprotech, 300-07), Flt3-ligand (Peprotech, 
300-19), and thrombopoietin (Peprotech, 300-18). On day 2, CD34+ cells were nucleofected per manufacturer’s 
instructions with the P3 Primary Cell Nucleofection Kit (Lonza, V4XP-3012), with the addition of 25 μg of  
TrueCut Cas9 Protein v2 (Thermo Fisher Scientific, A36499) and 50 μg of CD7-gRNA (custom synthesized 
from Trilink), using a 4D-Nucleofector Core Unit (Lonza, AAF-1002B) program EO-100. The CD7-gRNA 
sequence is as follows: 5′-ATCACGGAGGTCAATGTCTA-3′. Of note, 2′-O-methyl and 3′ phosphorothioate 
bases were incorporated at the 3 terminal bases of the 5′ and 3′ ends of the gRNA to increase stability. Control 
CD34+ cells were nucleofected with Cas9 protein only. Cells were incubated at 32°C overnight. On day 3, cells 
were injected i.v. into mice as detailed below. A small fraction of cells was plated on Human Methylcellulose 
Enriched Media (R&D Systems, HSC005), and colonies were harvested after 14–16 days. DNA was extracted 
for evaluation of CD7 gene mutations by NGS.
Molecular analysis. Genomic DNA was isolated from colonies derived from HSCs in vitro, or peripheral 
blood obtained from mice engrafted with HSCs in vivo, using the DNeasy Blood & Tissue Kit (Qiagen, 69504). 
Samples were submitted to the Washington University Genome Engineering and iPSC Center (St. Louis, Mis-
souri, USA) for NGS to detect mutations in the CD7 gene.
In vivo engraftment of  HSCs. Nonobese diabetic (NOD)/severe combined immunodeficient (SCID)/common 
γ chain–/–(γc−/−) (NSG, The Jackson Laboratory, 005557), NSG–huIL-15 (NSG mice expressing human IL-15; 
The Jackson Laboratory, 030890), or NSGS mice (NSG mice expressing human IL-3, GM-CSF, and SCF; The 
Jackson Laboratory, 013062) were sublethally irradiated with 250 cGy followed by i.v. injection with 5 × 104 to 1 
× 105 CD34+ cells per mouse. Human cell engraftment was assessed by serial blood collections at 4, 8, 12, 15–16, 
and 19–20 weeks after CD34+ cell injection.
T cell in vitro functional studies. Splenocytes harvested from control or CD7-KO HSC–engrafted mice were 
used for the following studies. Detection of intracellular phosphorylated proteins (pErk1/2, pSTAT5) in response 
to PMA (400 nM, Sigma-Aldrich, P8139-1MG) or IL-2 (100 ng/mL, PeproTech, 200-02-1 mg) was performed 
using the BD Phosflow T Cell Activation Kit (BD Biosciences, 560750) according to the manufacturer’s instruc-
tions. Measurement of degranulation and intracellular cytokine production was performed by treating cells with 
PMA (50 nM) and ionomycin (1 μg/mL) and incubating with CD107a-FITC (clone eBioH4A3, eBioscience, 
11-1079-41), monensin, anti-CD49d (clone 9F10, BD Biosciences, 555501), and anti-CD28 (clone CD28.2, BD 
Biosciences, 555725) for 4 hours. Cells were then harvested and stained with CD3-PE/Cy7 (clone UCHT1, 
eBioscience, 25-0038-41), CD7-APC (clone M-T701, BD Biosciences, 561604), and LIVE/DEAD fixable yel-
low (Thermo Fisher Scientific, L34967). Subsequently, cells were treated with the Invitrogen Fix & Perm Cell 
Permeabilization Kit (Thermo Fisher Scientific, GAS003), followed by intracellular staining with IFN-γ–PE 
(clone 4S.B3, BioLegend, 502510), GM-CSF–BV421 (clone BVD2 21C11, BD Biosciences, 562930), TNF-α–
AF700 (clone Mab11, BioLegend, 502928), MIP1b-APC/H7 (BD Biosciences, 561280), and IL-2–PE–CF594 
(clone 5344.111, BD Biosciences, 562384). Samples were analyzed by flow cytometry after staining completed.
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Expansion of  CD7-KO T cells. Human T were sorted from splenocytes harvested from control or CD7-KO 
HSC–engrafted NSGS mice based on expression of human CD45 and CD3, using a MoFlo cell sorter (Beckman 
Coulter) or a SY3200 Synergy HAPS cell sorter (Sony Biotechnology). Cells were cultured in R10 media with the 
addition of anti-CD3/CD28 beads at a 3:1 bead/cell ratio, and they were counted every 2 days to maintain cell 
density less than 1 × 106 cells/mL. Flow cytometry was performed 3 days after activation to assess CD7 expression.
NK cell in vitro tumor killing assay. Human NK cells were sorted from splenocytes harvested from control or 
CD7-KO HSC–engrafted NSG-huIL-15 mice based on expression of human CD45 and CD56, using a SY3200 
Synergy HAPS cell sorter (Sony Biotechnology). Control and CD7-KO NK cells were evaluated using IncuCyte 
Live-cell Analysis system. In total, 5000 UM-SCC-9 cells expressing CBR/GFP were incubated for 2 hours in 
a 96-well plate and imaged prior to the addition of the NK cells at a 5:1 and 10:1 E:T ratio. Real-time images 
were captured every 3 hours and up to 72 hours, and they were analyzed using the Incucyte software. Data are 
presented as green object counts (GFP+ UM-SCC-9 tumor cells).
Administration of  NT-I7 to HSC-engrafted mice. NSGS mice were engrafted with control or CD7-KO HSCs 
followed by serial injections of 10 mg/kg NT-I7 (NeoImmuneTech Inc.) s.c. starting 1 week after CD34+ cell 
injection. NT-I7 injections were continued every 2 weeks for 7 doses, total. Blood was collected from the mice at 
4, 8, 12, and 15 weeks after CD34+ cell injection as detailed above.
In vivo treatment with UCART7. T cell engraftment was confirmed in NSGS mice at approximately 15–16 
weeks after CD34+ cell injection, after which, 2 × 106 UCART7 cells were injected i.v. and blood was collected 
weekly for 2–4 weeks. Alternatively, mice were injected with 2 × 105 CCRF-CEM cells (ATCC, CCL-119) that 
had been engineered to express CBR/GFP to facilitate tracking of tumor. UCART7 was injected 1 week after 
tumor was established. Tumor burden was monitored longitudinally by bioluminescence imaging using an Ami 
HT optical imaging system (Spectral Instruments).
Flow cytometry. The following antibodies were used to assess %CD7 on PBMCs by flow cytometry: CD3-
PE/Cy7 (clone UCHT1, eBioscience, 25-0038-41), CD4-FITC (clone RPA-T4, BioLegend, 300506), CD7-APC 
(clone M-T701, BD Biosciences, 561604), CD8-BV421 (clone RPA-T8, BioLegend, 301036), CD56-PE (clone 
5.1H11, BioLegend, 362508), and LIVE/DEAD fixable yellow (Thermo Fisher Scientific, L34967).
Memory subsets on T cells were quantified using the following antibodies: CD3-PE/Cy7 (clone UCHT1, 
eBioscience, 25-0038-41), CD4-BV650 (clone SK3, BD Horizon, 563875), CD7-PE (clone M-T701, BD Bio-
sciences, 555361), CD8-AF700 (clone HIT8a, BioLegend, 300920), CD56-FITC (clone HCD56, BioLegend, 
318304), CD45RO-BV421 (clone UCHL1, BioLegend, 304224), CD197-AF647 (clone G043H7, BioLegend, 
353218), and LIVE/DEAD fixable yellow (Thermo Fisher Scientific, L34967).
Peripheral blood obtained from mice were lysed in ACK lysis buffer, and human cell engraftment was 
assessed by flow cytometry using the following antibodies: CD3-PE/Cy7 (clone UCHT1, eBioscience, 25-0038-
41), CD4-FITC (clone RPA-T4, BioLegend, 300506), CD7-APC (clone M-T701, BD Biosciences, 561604), 
CD8-PerCP/Cy5.5 (clone RPA-T8, BioLegend, 301032), CD19-BV605 (clone HIB19, BioLegend, 302244), 
CD33-BV711 (clone WM53, BD Biosciences, 563171), mouse CD45-APC/Cy7 (clone 30-F11, BioLeg-
end, 103116), human CD45-BV421 (clone HI30, BioLegend, 304032), CD56-PE (clone 5.1H11, BioLegend, 
362508), and LIVE/DEAD fixable yellow (Thermo Fisher Scientific, L34967).
After UCART7 injections, the panel was modified as follows: CD3-PE/Cy7 (clone UCHT1, eBioscience, 
25-0038-41), CD4-BV650 (clone SK3, BD Horizon, 563875), CD7-APC (clone M-T701, BD Biosciences, 
561604), CD34-PE (clone QBEnd10 + Immu133 + Immu409, Beckman Coulter, IM1459U), CD56-FITC (clone 
HCD56, BioLegend, 318304), mouse CD45-APC/Cy7 (clone 30-F11, BioLegend, 103116), human CD45-
BV421 (clone HI30, BioLegend, 304032), and LIVE/DEAD fixable yellow (Thermo Fisher Scientific, L34967).
Mice injected with tumor followed by UCART7 were assessed with the following panel: tumor-GFP, CD3-
PE/Cy7 (clone UCHT1, eBioscience, 25-0038-41), CD4-PerCP/Cy5.5 (clone RPA-T4, BioLegend, 300530), 
CD7-APC (clone M-T701, BD Biosciences, 561604), CD34-PE (clone QBEnd10 + Immu133 + Immu409, 
Beckman Coulter, IM1459U), CD56-BV605 (clone HCD56, BioLegend, 318334), mouse CD45-APC/Cy7 
(clone 30-F11, BioLegend, 103116), human CD45-BV421 (clone HI30, BioLegend, 304032), and LIVE/DEAD 
fixable yellow (Thermo Fisher Scientific, L34967).
Human NK cells derived from control or CD7-KO HSCs were assessed using the following antibod-
ies: CD16-FITC (clone 3G8, Thermo Fisher Scientific, MHCD1601), CD3-ECD (clone UCHT1, Beckman 
Coulter, IM2705U), mouse CD45-PerCP/Cy 5.5 (clone 30-F11, BD Biosciences, 550994), CD56-PE/Cy7 
(clone N901, Beckman Coulter, A51078), CD7-APC (clone M-T701, BD Biosciences, 561604), KIR2DL1/
DS1-VioBlue (clone 11PB6, Miltenyi, 130-125-246), KIR2DL2/L3/S2-BV421 (clone CH-L, BD Pharmingen, 
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743451) KIR3DL1-BV421 (clone DX9, BD Pharmingen, 742979), human CD45-KO (clone J33, Beckman 
Coulter, A96416), and LIVE/DEAD zombie NIR (BioLegend, 423105).
Samples were run on an Attune NxT Flow Cytometer (Thermo Fisher Scientific) or a Gallios Flow Cytom-
eter (Beckman Coulter). Analysis was performed using FlowJo 10.6.1 (Tree Star Inc.).
Off-target mutation analysis. In silico off-target sites (Table 1) were selected using 2 different prediction algo-
rithms: CCTop (https://cctop.cos.uni-heidelberg.de:8043/) (30) and Cas-OFFinder (http://www.rgenome.net/
cas-offinder/) (31). GUIDE-seq sites were previously published. A full list of off-target sequences queried are 
as follows: CD7, ATCACGGAGGTCAATGTCTA (on-target); PACRG, TTTTATGGTTATCTTTATAA 
(GUIDEseq); ARHGEF4, CAAACGATATTGTGGCCAAA (GUIDEseq); HMGB1P22, TTTAAAATA-
ATTAATAATAC (GUIDEseq); CCBE1, TCCCGGTCATATCGGTATCC (GUIDEseq); AC016907.3, 
CACAAGGAAGTCAATGTCTA (in silico); RP11-92A5.2, ATCAGGGAGGAAAATGTCTA (in silico); 
CTA-254O6.1, AGGACAGAGATCAATGTCTA (in silico); RPS3AP52, ATCTAGAGGGTCAATGTCTA 
(in silico); and FUNDC2P2, ATCACGGAGGGACAATTTCTA (in silico).
Genomic DNA was obtained from matched donor control or CD7-KO HSCs after in vitro differentiation 
on methylcellulose. NGS was performed after PCR amplification of each off-target site. Read counts at each 
off-target site ranged from 173 to 9911 (median, 6185). When assessing for mutations, we excluded single nucle-
otide polymorphisms that were defined as single-bp changes occurring in both control and KO samples for an 
individual donor at approximately 50% or 100% frequency.
Statistics. All statistical analyses were performed using GraphPad Prism v9 for macOS. Unpaired, 2-tailed 
Student’s t test, paired 2-tailed Student’s t test, 1-way ANOVA, and 2-way ANOVA were used to compare groups 
as detailed in the figure legends. Significance was defined as a P value of less than 0.05.
Study approval. All animal studies were approved by the IACUC at Washington University (protocol no. 
20180005).
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